According to Cosmo Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 67.4885. At the end of 2022 the company had a P/E ratio of 55.2.
Year | P/E ratio | Change |
---|---|---|
2022 | 55.2 | 29.74% |
2021 | 42.5 | -137.1% |
2020 | -115 | 208.44% |
2019 | -37.2 | -34.07% |
2018 | -56.4 | 19.54% |
2017 | -47.2 | -143.22% |
2016 | 109 | 1312.07% |
2015 | 7.73 | 238.52% |
2014 | 2.28 | 6.71% |
2013 | 2.14 | -71.9% |
2012 | 7.61 | -63.45% |
2011 | 20.8 | -51.81% |
2010 | 43.2 | 57.48% |
2009 | 27.4 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.